Li Fang Liu

US Patent:

6569638, May 27, 2003

Filed:

Mar 3, 2000

Appl. No.:

09/517734

Inventors:

I. Bernard Weinstein - Englewood NJ
W. Joseph Thompson - Doylestown PA
Jae-Won Soh - Cliffside Park NJ
Li Liu - Ambler PA
Han Li - Yardley PA

Assignee:

Cell Pathways, Inc - Horsham PA

International Classification:

C12Q 148

US Classification:

435 15, 435 692, 435184

Abstract:

This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.

US Patent:

7154670, Dec 26, 2006

Filed:

Mar 10, 2004

Appl. No.:

10/796930

Inventors:

Hongbin Zhang - Marlboro NJ, US
Li Liu - Carneys Point NJ, US
R. Brian Jander - Freehold NJ, US
Alexei N. Pilipetskii - Colts Neck NJ, US

Assignee:

Tyco Telecommunications (US) Inc. - Morristown NJ

International Classification:

G02B 27/28

US Classification:

359501, 359497, 385 11

Abstract:

Methods and apparatus of performing polarization control for optical transmissions. The methods and apparatus enable polarization control devices to achieve a desired output state of polarization regardless of the input state of polarization. The desired state of polarization can be achieved by rotating waveplates in a polarization controller in a sequential fashion. Each waveplate may be continually adjusted or dithered so long as the feedback signal satisfies a feedback condition. Once the feedback signal exceeds the feedback condition, the next waveplate in the polarization controller is adjusted. This enables the methods and apparatus to rapidly adjust the state of polarization away from dead spots and minimize loss control problems.

US Patent:

8513423, Aug 20, 2013

Filed:

Oct 20, 2011

Appl. No.:

13/277702

Inventors:

Peter J. Connolly - New Providence NJ, US
Haiyan Bian - Princeton NJ, US
Xun Li - New Hope PA, US
Li Liu - Germantown MD, US
Mark J. Macielag - Gwynedd Valley PA, US
Mark E. McDonnell - Lansdale PA, US

Assignee:

Janssen Pharmaceutica, NV

International Classification:

C07D 401/00
A61K 31/00

US Classification:

546208, 51421018

Abstract:

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows:.

US Patent:

20130123232, May 16, 2013

Filed:

Dec 18, 2012

Appl. No.:

13/718056

Inventors:

JANSSEN PHARMACEUTICA NV - New Brunswick NJ, US
Kristen Chevalier - Collegeville PA, US
Jose Clemente - Spring House PA, US
Pete Connolly - Spring House PA, US
Chris Flores - Spring House PA, US
Shu-Chen Lin - Doylestown PA, US
Li Liu - Doylestown PA, US
John Mabus - East Greenville PA, US
Mark Macielag - Spring House PA, US
Mark McDonnell - Lansdale PA, US
Philip Pitis - North Wales PA, US
Yue-Mei Zhang - Spring House PA, US
Sui-Po Zhang - Radnor PA, US
Bin Zhu - Spring House PA, US

Assignee:

JANSSEN PHARMACEUTICA NV - New Brunswick NJ

International Classification:

C07D 417/12
C07D 401/10
C07D 471/04
C07D 403/14
C07D 403/06
C07D 495/04
C07D 417/14
C07D 417/06

US Classification:

51421018, 544369, 544364, 544363, 544371, 544373, 544362

Abstract:

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:wherein Y, Z, R, and s are defined herein.

US Patent:

20130137674, May 30, 2013

Filed:

Jan 25, 2013

Appl. No.:

13/749846

Inventors:

Janssen Pharmaceutica, NV - New Brunswick NJ, US
Kristen Chevalier - Collegeville NJ, US
Jose Clemente - Spring House PA, US
Peter Connolly - Spring House PA, US
Christopher Flores - Spring House PA, US
Shu-Chen Lin - Doylestown PA, US
Li Liu - Germantown MD, US
John Mabus - East Greenville PA, US
Mark Macielag - Spring House PA, US
Mark McDonnell - Lansdale PA, US
Philip Pitis - North Wales PA, US
Yue-Mei Zhang - Belle Mead NJ, US
Sui-Po Zhang - Radnor PA, US
Bin Zhu - Spring House PA, US

Assignee:

Janssen Pharmaceutica, NV - New Brunswick NJ

International Classification:

C07D 417/14
C07D 403/14
C07D 409/14
C07D 403/04
C07D 401/14

US Classification:

51421018, 544359, 544364, 544369, 544379, 544363, 544372, 544 586, 544373

Abstract:

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:wherein Y, Z, R, and s are defined herein.

US Patent:

55939996, Jan 14, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/480814

Inventors:

Madhavan G. Nair - Mobile AL
Li Liu - Mobile AL

International Classification:

C07D40106
C07D40906
C07D40506
C07D23990

US Classification:

514260

Abstract:

Several new 10-formyl and 10-hydroxymethyl derivatives of 5,8,10-trideazapteroic acid are provided, as well as procedures for their preparation. These compounds were shown to be powerful inhibitors of glycinamide ribonucleotide formyltransferase (GARFT), an enzyme that mediates the de novo biosynthesis of purine nucleotides that are required for DNA synthesis and cell division. Due to their ability to interfere with nucleotide biosynthesis and to penetrate microbial cells they are potential anti-microbial agents and are useful for the treatment of opportunistic infections in AIDS and other infections caused by micro-organisms that are resistant to conventional anti-bacterial and anti-fungal agents.

US Patent:

20210404012, Dec 30, 2021

Filed:

Feb 1, 2021

Appl. No.:

17/164336

Inventors:

- Leverkusen, DE
- Berlin, DE
Bernard HÄNDLER - Berlin, DE
Sven GOLFIER - Berlin, DE
Andreas SCHLICKER - Berlin, DE
Li LIU - East Hanover NJ, US

Assignee:

Bayer Aktiengesellschaft - Leverkusen
Bayer Pharma Aktiengesellschaft - Berlin

International Classification:

C12Q 1/6886
A61P 35/00
A61K 31/5377

Abstract:

The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject. Preferably the hyper-proliferative disease or the subject is characterized by one or more biomarker(s) selected fromThe present invention also covers a kit comprising Compound A together with means to detect one or more of the aforementioned biomarker(s) and a method for identifying a subject having a hyper-proliferative disease disposed to respond favorably to Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s). Further, the invention covers a method of determining whether a subject having a hyper-proliferative disease will respond to the treatment with Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s) in a sample of the subject.

US Patent:

20200375997, Dec 3, 2020

Filed:

Dec 4, 2018

Appl. No.:

16/770462

Inventors:

- Leverkusen, DE
Gerhard SIEMEISTER - Berlin, DE
Li LIU - East Hanover NJ, US

Assignee:

Bayer Aktiengesellschaft - Leverkusen

International Classification:

A61K 31/5377
C12Q 1/6886
A61P 35/00

Abstract:

The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.